The malpractice and breach of contract class action filed Tuesday against Grant & Eisenhofer and name partner Jay Eisenhofer raises some troubling questions--but they're not necessarily the troubling questions the lawyers who filed the suit wanted to raise.

This could be a game changer, folks--and it couldn't come at a more critical moment for opponents of the deals that keep generic drugs off the market.

David B. Saxe, J.P. Eugene Nardelli John T. Buckley James M. Catterson, JJ. 3501-3501A Index 601272/06 In re: Comverse Technology, Inc., Derivative Litigation Leonard Sollin

Appearances Plaintiffs' Lead Counsel for Consolidated Securities Class Action: By: Donald R. Hall, Jr., Esq., Frederic Scott Fox, Esq., Robert N. Kaplan, Esq., Kaplan Fox & Kils

Supreme Court of the State of New York Appellate Division: Second Judicial Department WILLIAM F. MASTRO, J.P. HOWARD MILLER DANIEL D. ANGIOLILLO LEONARD

Eugene Nardelli John W. Sweeny, Jr. Bernard J. Malone, Jr., JJ. 1931 Index 104553/05 Sam Wyly, Petitioner-Respondent, v Milberg Weiss Bershad & Schulman,

For close to two years, counsel for Bank of America at Cleary Gottlieb and Wachtell Lipton have been struggling--and largely failing--to tame consolidated securities, ERISA, and derivative litigation over BofA's 2008 merger with Merrill Lynch. Will Brad Karp, Ted Wells, and their partners at Paul Weiss fare any better?